VYNE Therapeutics (VYNE) Other Operating Expenses (2016 - 2020)

VYNE Therapeutics' Other Operating Expenses history runs 4 years deep, the most recent figure standing at $139.1 million for Q2 2020.

• Quarterly Other Operating Expenses changed N/A year-over-year to $139.1 million in Q2 2020, while the trailing twelve-month figure through Mar 2021 was $139.1 million (up 989.49% YoY) and the FY2020 annual result came in at $139.1 million, changed N/A from the prior year.
• Other Operating Expenses was $139.1 million for Q2 2020 at VYNE Therapeutics, up from -$15.6 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $139.1 million in Q2 2020 and bottomed at -$15.6 million in Q4 2019.
• A 4-year average of $28.9 million and a median of -$4.0 million in 2016 frame the typical range for Other Operating Expenses.
• Peak annual rise in Other Operating Expenses reached 17.45% in 2019, while the deepest fall reached 17.45% in 2019.
• VYNE Therapeutics' Other Operating Expenses stood at $5.4 million in 2016, then sank by 347.71% to -$13.3 million in 2018, then decreased by 17.45% to -$15.6 million in 2019, then jumped by 989.49% to $139.1 million in 2020.
• Business Quant data shows VYNE's Other Operating Expenses at $139.1 million in Q2 2020, -$15.6 million in Q4 2019, and -$13.3 million in Q4 2018.